ChristopherCogleMD
Oncology • Gainesville, FLHematologic Oncology
Professor of Medicine, University of Florida
Dr. Cogle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 SW Archer Road
Gainesville, FL 32608Phone+1 352-273-7832Fax+1 352-273-5006
Summary
- I am a board certified medical oncologist with clinical specialization in hematological malignancies and blood & marrow transplant. My laboratory research is focused on drug development for AML and MDS, oncolytic virotherapy for cancer and GVHD, and using cancer genomics for personalizing treatment for cancer patients. I've invented new epidemiological tools for improved cancer case identification in large populations. In healthy policy, I chair the Florida Cancer Council and am a member of the National Academies National Cancer Policy Forum.
Clinical Expertise
- Sarcomas, Acute myeloid leukemia, Myelodysplastic syndromes , Myeloproliferative neoplasms, Cancer genetics, Computational biology, Drug development, Aplastic anemia, Bone marrow failure syndromes, Myeloproliferative disorders, Stem cell transplantation
Education & Training
Duke University HospitalPost-Doctoral Fellowship, 2003 - 2003
University of FloridaFellowship, Hematology and Medical Oncology, 2000 - 2003- University of FloridaResidency, Internal Medicine, 1997 - 2000
- University of Florida College of MedicineClass of 1997
Certifications & Licensure
FL State Medical License 1998 - 2025
GA State Medical License 2008 - 2010
NC State Medical License 2003 - 2004- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS Start of enrollment: 2011 Feb 01
- iCare for Cancer Patients Start of enrollment: 2015 Jun 26
- Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Start of enrollment: 2015 Dec 02
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsPrevalence of Underreported Nicotine Exposure Among US Nonsmoking Adults: A Comparison of Self-Reported Exposure and Serum Cotinine Levels From NHANES 2013-2020.Ruixuan Wang, Jaclyn M Hall, Ramzi G Salloum, Frederick Kates, Christopher R Cogle
Nicotine & Tobacco Research. 2024-02-22 - 1 citationsTransplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in...Benjamin Tomlinson, Marcos de Lima, Christopher R Cogle, Michael A Thompson, David L Grinblatt
Transplantation and Cellular Therapy. 2023-07-01 - 5 citationsGenome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.Nam H K Nguyen, Roya Rafiee, Abderrahmane Tagmount, Amin Sobh, Alex Loguinov
Blood Advances. 2023-05-09
Journal Articles
- Clinical Application of Computational Methods in Precision OncologyMia A Levy, Christopher R Cogle, JAMA Oncology
- Functional Genomic Landscape of Acute Myeloid LeukaemiaMarc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature
Abstracts/Posters
- Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) ...Christopher R. Cogle, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- CRISPR Dropout Screens Identify DHODH, PIK3C3, and Crkl as Potential Therapeutic Targets in Acute Myeloid LeukemiaChristopher R. Cogle, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) T...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Clinical Application of Computational Methods in Precision OncologyMay 2020
- Clinical Application of Computational Methods in Precision OncologyMay 2020
Press Mentions
OncoMyx Announces Exclusive Option to License Intellectual Property Rights for Myxoma Virus Technology from University of FloridaJune 15th, 2021
Grant Support
- Defining The Human HemangioblastNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2009
Committees
- Member, National Cancer Policy Forum 2017 - Present
- Chairperson, Florida Cancer Control and Research Advisory Council (CCRAB) 2016 - Present
Professional Memberships
- Member
External Links
- Websitehttp://cogle.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
